PDL – Depomed’s deal for type 2 diabetes products
PDL BioPharma, Inc. (PDL) announces an amendment to the Royalty Purchase and Sale Agreement (the “Royalty Agreement”) with Depomed, Inc. (Depome”) under... Read More
Case Study: LEO Pharma’s acquisition of Bayer’s dermatology unit
LEO Pharma has entered into a definitive agreement to buy Bayer’s global prescription dermatology unit. The portfolio to be acquired includes branded... Read More
Daiichi Sankyo, Glycotope to develop gatipotuzumab antibody drug conjugate
Daiichi Sankyo Company, Limited and Glycotope GmbH have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC)... Read More
Is COPP and FSC is same?
Posted on30 Jul 2018
Comments0
COPP stands for certificate of pharmaceutical products and FSC stands for free sale certificate. Certificate of a Pharmaceutical Product (COPP) The COPP... Read More
Case Study on USFDA Label Expansion: Novartis’ Kisqali
FDA had approved Kisqali in tandem with an aromatase inhibitor as an initial endocrine-based treatment for pre, peri- or postmenopausal women with... Read More
Case Study: Novartis Pharma’s global licensing deal to develop & commercialise MOR106
MOR106 is an investigational, fully human, IgG1 monoclonal antibody directed against the target IL-17C that was generated in a collaboration between MorphoSys... Read More
EUSA Pharma acquires global rights to Sylvant from Janssen Sciences for US$ 15 mn
EUSA Pharma (EUSA), a biopharmaceutical company focused on oncology and rare disease, has entered into a definitive agreement with Janssen Sciences Ireland... Read More
Aurobindo acquires Apotex Inc’s business in 5 European countries for €74 mn
Posted on15 Jul 2018
Comments0
Aurobindo Pharma Limited, step-down subsidiary, Agile Pharma B V (Netherlands), signed a definitive agreement to acquire Canadian pharmaceuticals company Apotex International Inc’s... Read More
Bayer’s strategic alliance with Broad Institute of MIT and Harvard
Bayer and the Broad Institute of MIT and Harvard announced the launch of the joint Precision Cardiology Laboratory, which will pursue novel... Read More
Benitec’s Axovant exclusive rights to gene therapy for OPMD
Axovant Sciences announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the... Read More